Logo image of TXMD

THERAPEUTICSMD INC (TXMD) Stock Fundamental Analysis

NASDAQ:TXMD - Nasdaq - US88338N2062 - Common Stock - Currency: USD

1.11  -0.01 (-0.89%)

Fundamental Rating

3

Taking everything into account, TXMD scores 3 out of 10 in our fundamental rating. TXMD was compared to 194 industry peers in the Pharmaceuticals industry. While TXMD seems to be doing ok healthwise, there are quite some concerns on its profitability. TXMD is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

TXMD had negative earnings in the past year.
TXMD had a positive operating cash flow in the past year.
In the past 5 years TXMD reported 4 times negative net income.
TXMD had negative operating cash flow in 4 of the past 5 years.
TXMD Yearly Net Income VS EBIT VS OCF VS FCFTXMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

With a decent Return On Assets value of -5.49%, TXMD is doing good in the industry, outperforming 74.23% of the companies in the same industry.
With a decent Return On Equity value of -7.85%, TXMD is doing good in the industry, outperforming 78.35% of the companies in the same industry.
Industry RankSector Rank
ROA -5.49%
ROE -7.85%
ROIC N/A
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TXMD Yearly ROA, ROE, ROICTXMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

TXMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TXMD Yearly Profit, Operating, Gross MarginsTXMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

6

2. Health

2.1 Basic Checks

TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
TXMD has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, TXMD has more shares outstanding
TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TXMD Yearly Shares OutstandingTXMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
TXMD Yearly Total Debt VS Total AssetsTXMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -34.18, we must say that TXMD is in the distress zone and has some risk of bankruptcy.
TXMD's Altman-Z score of -34.18 is on the low side compared to the rest of the industry. TXMD is outperformed by 86.60% of its industry peers.
There is no outstanding debt for TXMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -34.18
ROIC/WACCN/A
WACC10.13%
TXMD Yearly LT Debt VS Equity VS FCFTXMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TXMD has a Current Ratio of 2.64. This indicates that TXMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TXMD (2.64) is comparable to the rest of the industry.
TXMD has a Quick Ratio of 2.64. This indicates that TXMD is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.64, TXMD perfoms like the industry average, outperforming 50.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.64
Quick Ratio 2.64
TXMD Yearly Current Assets VS Current LiabilitesTXMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 73.12% over the past year.
TXMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 52.78%.
TXMD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -48.72% yearly.
EPS 1Y (TTM)73.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.51%
Revenue 1Y (TTM)52.78%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%25.56%

3.2 Future

Based on estimates for the next years, TXMD will show a decrease in Earnings Per Share. The EPS will decrease by -8.87% on average per year.
The Revenue is expected to grow by 1.92% on average over the next years.
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TXMD Yearly Revenue VS EstimatesTXMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
TXMD Yearly EPS VS EstimatesTXMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20 -30

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TXMD. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 6.40, the valuation of TXMD can be described as very cheap.
Based on the Price/Forward Earnings ratio, TXMD is valued cheaper than 92.27% of the companies in the same industry.
TXMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.21.
Industry RankSector Rank
PE N/A
Fwd PE 6.4
TXMD Price Earnings VS Forward Price EarningsTXMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, TXMD is valued cheaper than 91.75% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.13
EV/EBITDA N/A
TXMD Per share dataTXMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

A cheap valuation may be justified as TXMD's earnings are expected to decrease with -18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%

0

5. Dividend

5.1 Amount

TXMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

THERAPEUTICSMD INC

NASDAQ:TXMD (8/1/2025, 8:07:54 PM)

1.11

-0.01 (-0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08
Earnings (Next)08-11 2025-08-11
Inst Owners44.06%
Inst Owner Change0%
Ins Owners1.55%
Ins Owner Change0.18%
Market Cap12.84M
Analysts43.33
Price TargetN/A
Short Float %0.16%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.4
P/S 6.98
P/FCF 9.13
P/OCF 9.13
P/B 0.48
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)0.17
Fwd EY15.62%
FCF(TTM)0.12
FCFY10.96%
OCF(TTM)0.12
OCFY10.96%
SpS0.16
BVpS2.31
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.49%
ROE -7.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 76.43%
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.64
Quick Ratio 2.64
Altman-Z -34.18
F-Score7
WACC10.13%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.51%
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue 1Y (TTM)52.78%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%25.56%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%
EBIT growth 1Y55.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y117.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.2%
OCF growth 3YN/A
OCF growth 5YN/A